Prana Biotechnology Ltd., of Melbourne, Australia, received a notice of allowance for a patent, titled "Neurologically Active Compounds." It covers the composition of matter for selected 8-hydroxy quinazolinone compounds, including lead Parkinson's disease candidate PBT434.